Upcoming Events
This September, our team will be attending the European Peptide Society’s 38th European Peptide Symposium 2026 to connect with other scientific and industry experts and present insights in our differentiated detangler approach aiming to inhibit and reverse disease-specific protein aggregation.
Our colleague Mathias Wendt, Senior Peptide Chemist, will present a poster highlighting the potential of our all-D-peptide platform to provide new disease-modifying options for patients with neurodegenerative disorders. In addition, our Director Preclinical Development, Antje Willuweit, will also be on-site and is looking forward to discussing our differentiated pipeline programs and latest clinical and preclinical data.
Details of the poster presentation:
- Title: Targeting Neurodegenerative Diseases with Priavoid’s Peptide Drug Development Platform
- Date & time: Tuesday, September 8, 2026; 17:30-19:30
- Poster number: #317
If you are attending EPS 2026 and would like to learn more about Priavoid’s work, please feel free to get in touch via media@priavoid.com to arrange a meeting.
About Priavoid
Priavoid’s novel class of orally available all-D-peptide therapeutics detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders. We aim to establish clinical proof-of-concept through our lead program, PRI-002, which will complete a Phase 2 trial in Alzheimer’s disease in 2026. Priavoid has built a focused pipeline of detangler compounds that are non-immunogenic and reach their oligomer targets in the brain and inside the affected cells. Our goal is to develop disease-modifying therapies that address the underlying biology of neurodegeneration and drive meaningful clinical benefit for patients.